Irritable Bowel SyndromeNCT07033936
Prevalence of Irritable Bowel Syndrome Among Egyptian Medical Students
An observational study of Irritable Bowel Syndrome, run by Zagazig University at 1 site in Egypt.
Trial summary
Assess prevalence of irritable bowel syndrome among both medical students and medical interns, and the most significant risk factors of this condition, and highlight the association between IBS symptoms, anxiety \& depression. Read more about this study
- Who is it for?
- Ages 18 to 27 yearsHealthy volunteers can take part
- Conditions the study is for
- Irritable Bowel Syndrome
- What is being tested?
- Questionnaire
- How many people
- 1,093 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Jun 2025to 6 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 27 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Egyptian Medical students and Intern
Who may be able to join
- Egyptian Medical students and interns
- Their age ranges from 18 to 29 years
- Have access to online platforms such as Facebook, WhatsApp, and Telegram.
- Accept to participate in the questionnaire
Who cannot join
- Participate who refused to participate
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Zagazig University Faculty of Medicine and Affiliated Hospital
Zagazig
About this study
Official title: Prevalence Of Irritable Bowel Syndrome, Its Risk Factors, And Impact On Increasing Anxiety And Depression Among Egyptian Medical Students
Assess prevalence of irritable bowel syndrome among both medical students and medical interns, and the most significant risk factors of this condition, and highlight the association between IBS symptoms, anxiety \& depression.
Read the detailed description
One of the most common gastrointestinal disorders is irritable bowel syndrome (IBS). It is a chronic functional bowel disease in which abnormal bowel habits, such as diarrhea, constipation, or both, are associated with abdominal pain and distension. Around 11% of the general population suffers from their symptoms regardless of the geographical distribution.
Irritable bowel syndrome is more common among females and patients younger than 50. For medical students, IBS is common and may affect up to 25% of them.. Especially final-year students, due to the increasing workload of the final year.
Several risk factors increase the prevalence of irritable bowel syndrome, including environmental factors, life events, and junk food abuse. Also, Psychological disorders as severe levels of anxiety, depression, and stress, may contribute to the occurrence of irritable bowel syndrome, and this can be explained by the pathophysiology of IBS, maybe by brain-gut interaction.
Globally, the prevalence of anxiety and depression is higher in medical students compared to other populations, as it reaches up to 38.7% among them. Many factors play a role in increasing the prevalence of anxiety and depression among medical students as stressful courses in medical study, exposure to the death of patients, and others. In Egypt, the prevalence of medical students suffering from stress and anxiety is high due to several problems as financial problems, work overload, traditional methods of education, and the increasing number of students, making communication with thePage 3 of 9 lecturer difficult and that increase incidence of IBS among Egyptian medical students.
Just as anxiety is considered a risk factor for the development of Irritable Bowel Syndrome (IBS), IBS can also lead to the occurrence of anxiety and depression, and that can be explained by brain-gut interaction.
Patients with IBS have a three-times increased risk of either anxiety or depression, compared to healthy subjects.
Although the importance of this topic is recognized, there are limited data about the exact prevalence of irritable bowel syndrome among medical students in Egypt.
Previous studies have discussed this topic in three medical schools in Egypt, but their sample size were too small, and they did not assess the associated anxiety and depression among these students, so no definitive conclusion can be made. This is the first study in Zagazig University hospital to assess the prevalence of irritable bowel syndrome among both medical students and medical interns, and the most significant risk factors of this condition, and highlight the association between IBS symptoms and anxiety and depression.
- Conditions
- Irritable Bowel Syndrome
- Being tested
- Questionnaire
- Medical subject headings
- Irritable Bowel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
An online Questionnaire will be shared via social media such as WhatsApp, Facebook or X for Egyptian medical students and intern to fill
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of irritable bowel syndrome patients among population
Will use Rome IV criteria to diagnose IBS. It is composed of three questions about the presence of GIT symptoms. The presence of at least two of the three diagnoses the IBS.
Measured: 1 month
Secondary outcomes (1)
Number of IBS patients suffering anxiety and depression
Will use the HAD questionnaire to diagnose both anxiety and depression. It is a 14 questionnaire divided into two subscales, one for anxiety and the other for depression. Each question is composed of 4 answers, scored from 0 to 3. Cumulative score for each subscale determines the level of either anxiety or depression. an individual can score between 0 and 21 for either anxiety or depression, and be classified into the following categories: 0 to 7, normal; 8 to 10, borderline; and 11 to 21, abnormal (case)
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2025
- Study start10 Jun 2025
- Primary completion30 Jun 2025
- Study completion6 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Irritable Bowel SyndromeStudies of the same condition, open and under way.
- More trials run by Zagazig UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 1,093 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07033936
- Sponsor's protocol ID
- ZU-IRB # 1404/3-June-2025
- Status last verified
- Jun 2025
- First submitted
- 4 Jun 2025
- Last updated
- 8 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
PubMed 6880820
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence Of Irritable Bowel Syndrome, Its Risk Factors, And Impact On Increasing Anxiety And Depression Among Egyptian Medical Students
- ClinicalTrials.gov ID
- NCT07033936
- Acronym / sponsor ID
- ZU-IRB # 1404/3-June-2025
- Conditions
- Irritable Bowel Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,093 participants (actual)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 10 Jun 2025 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 6 Jul 2025 (actual)
- First posted
- 24 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assess prevalence of irritable bowel syndrome among both medical students and medical interns, and the most significant risk factors of this condition, and highlight the association between IBS symptoms, anxiety \& depression.
Detailed description
One of the most common gastrointestinal disorders is irritable bowel syndrome (IBS). It is a chronic functional bowel disease in which abnormal bowel habits, such as diarrhea, constipation, or both, are associated with abdominal pain and distension. Around 11% of the general population suffers from their symptoms regardless of the geographical distribution.
Irritable bowel syndrome is more common among females and patients younger than 50. For medical students, IBS is common and may affect up to 25% of them.. Especially final-year students, due to the increasing workload of the final year.
Several risk factors increase the prevalence of irritable bowel syndrome, including environmental factors, life events, and junk food abuse. Also, Psychological disorders as severe levels of anxiety, depression, and stress, may contribute to the occurrence of irritable bowel syndrome, and this can be explained by the pathophysiology of IBS, maybe by brain-gut interaction.
Globally, the prevalence of anxiety and depression is higher in medical students compared to other populations, as it reaches up to 38.7% among them. Many factors play a role in increasing the prevalence of anxiety and depression among medical students as stressful courses in medical study, exposure to the death of patients, and others. In Egypt, the prevalence of medical students suffering from stress and anxiety is high due to several problems as financial problems, work overload, traditional methods of education, and the increasing number of students, making communication with thePage 3 of 9 lecturer difficult and that increase incidence of IBS among Egyptian medical students.
Just as anxiety is considered a risk factor for the development of Irritable Bowel Syndrome (IBS), IBS can also lead to the occurrence of anxiety and depression, and that can be explained by brain-gut interaction.
Patients with IBS have a three-times increased risk of either anxiety or depression, compared to healthy subjects.
Although the importance of this topic is recognized, there are limited data about the exact prevalence of irritable bowel syndrome among medical students in Egypt.
Previous studies have discussed this topic in three medical schools in Egypt, but their sample size were too small, and they did not assess the associated anxiety and depression among these students, so no definitive conclusion can be made. This is the first study in Zagazig University hospital to assess the prevalence of irritable bowel syndrome among both medical students and medical interns, and the most significant risk factors of this condition, and highlight the association between IBS symptoms and anxiety and depression.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 27 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Egyptian Medical students and Intern
Key inclusion criteria (4 listed)
- Egyptian Medical students and interns
- Their age ranges from 18 to 29 years
- Have access to online platforms such as Facebook, WhatsApp, and Telegram.
- Accept to participate in the questionnaire
Key exclusion criteria (1 listed)
- Participate who refused to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireAn online Questionnaire will be shared via social media such as WhatsApp, Facebook or X for Egyptian medical students and intern to fill | Other | – |
Primary outcome
Number of irritable bowel syndrome patients among population
Time frame: 1 month
Will use Rome IV criteria to diagnose IBS. It is composed of three questions about the presence of GIT symptoms. The presence of at least two of the three diagnoses the IBS.
1 secondary outcome
Number of IBS patients suffering anxiety and depression
Time frame: 1 month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2025.
- Background: PubMed 6880820Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
Related trials for Irritable Bowel Syndrome
RecruitingObservational study
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
IBS (Irritable Bowel Syndrome), Rosacea
Recruiting
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
Irritable Bowel Syndrome
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Irritable Bowel Syndrome, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Irritable Bowel Syndrome, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of irritable bowel syndrome patients among population (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07033936, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2025.